SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Researchers, university tech transfer offices, pharmaceutical companies, and disease-focused philanthropic organizations often face a challenge in translating academic research projects into viable licensing candidates or start-up companies. Pappas Translational Medicine works hands-on with our partners to help identify, catalyze and manage those projects that have the best chance to become market-ready.
We target life science technologies and platforms with high potential to reach private-sector transaction-enabling milestones—with the goal of expanding the pipeline of high quality translational medicine programs.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.